Ginkgo Bioworks Financial Statements
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks revenue and earnings
In fiscal 2025, Ginkgo Bioworks generated $170.2 million in revenue, down 25.1% from fiscal 2024, its first annual decline since 2024. Ginkgo Bioworks reported a net loss of $312.8 million, compared with a loss of $547.0 million a year earlier. Operating margin was -185.3%.
Diluted earnings per share came in at -$5.64. Over the last 5 fiscal years, DNA's revenue has grown at a 17.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Ginkgo Bioworks income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 170.16M | 227.04M | 251.46M | 477.71M | 313.84M | 76.66M | 54.18M |
| Revenue growth (YoY) | -25.06% | -9.71% | -47.36% | +52.21% | +309.40% | +41.48% | — |
| Operating Expenses | 485.43M | 786.80M | 1.12B | 2.69B | 2.14B | 213.68M | 125.78M |
| Research & Development | 243.77M | 424.06M | 580.62M | 1.05B | 1.15B | 159.77M | 96.30M |
| Operating Income | -315.28M | -559.76M | -864.41M | -2.21B | -1.83B | -137.03M | -71.60M |
| Interest Expense | 0 | 94.00K | 93.00K | 106.00K | 2.37M | 2.38M | 2.42M |
| Other Income (Expense) | 1.68M | 12.25M | -28.53M | 87.55M | -9.65M | 12.19M | — |
| Pretax Income | -313.60M | -547.51M | -892.94M | -2.12B | -1.84B | -124.83M | -119.83M |
| Income Tax | -837.00K | -479.00K | -71.00K | -15.03M | -1.48M | 1.89M | 22.00K |
| Net Income | -312.76M | -547.03M | -892.87M | -2.10B | -1.83B | -126.61M | -119.33M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -5.64 | -10.54 | -18.37 | -50.15 | -1.35 | -0.10 | -0.10 |
| EPS (Diluted) | -5.64 | -10.54 | -18.37 | -50.20 | -1.39 | -0.10 | -0.10 |
| Shares Outstanding (Basic) | 55.46M | 51.89M | 48.61M | 41.98M | 1.36B | 1.27B | 1.15B |
| Shares Outstanding (Diluted) | 55.46M | 51.89M | 48.61M | 42.00M | 1.36B | 1.27B | 1.15B |
| EBITDA | -256.29M | -496.74M | -793.90M | -2.17B | -1.80B | -123.16M | -60.84M |
| Operating Margin | -185.29% | -246.54% | -343.76% | -462.41% | -582.62% | -178.75% | -132.14% |
| Net Margin | -183.81% | -240.94% | -355.08% | -440.63% | -583.12% | -165.16% | -220.23% |
This table shows 7 annual periods of Ginkgo Bioworks's income statement, from FY 2025 back to FY 2019, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow DNA's reporting calendar. What is a income statement?